DexCom’s Growth Prospects Meet Factory and Currency Risks
Zacks sees room for DexCom to grow, while flagging pressure from its Ireland factory ramp-up, foreign exchange and input costs.
Key takeaways
- Zacks cited DexCom’s product pipeline and international presence as growth drivers.
- Management expects nearly half of U.S. customers to move to G7 15-day by year-end 2026.
- The Ireland factory ramp-up and foreign-exchange movements may weigh on margins and reported revenue.
Zacks Equity Research sees growth potential for DexCom, citing the continuous glucose monitoring market, its international presence and product pipeline. It also flagged competition and operational risks. The article reported DexCom shares had gained 29.4% year to date, while the industry was down 5.7%.
DexCom’s second-quarter gross margin rose to 64.1%, up 4 percentage points from a year earlier, and its operating margin reached 25.1%, compared with 19.2%. Management raised full-year gross margin guidance to about 64% and operating margin guidance to 23.5%-24%.
Management expects nearly 50% of U.S. customers to transition to the G7 15-day system by the end of 2026. The G8 sensor remains on track for late 2027 or early 2028, subject to regulatory timing, according to the article.
Near-term costs could temper the margin gains. Hiring and training at the Ireland facility are expected to rise before production lines become operational, while management expects foreign-exchange movements to reduce international revenue by about $15 million in the second half of 2026 versus prior assumptions.
The article also cited delayed pressure from higher oil-linked input costs. Zacks Consensus Estimates put third-quarter revenue at $1.32 billion and earnings at 66 cents per share, implying year-over-year increases of 9.4% and 8.2%, respectively.
This article was produced with the help of AI technology. Source: Yahoo Finance
